A new study will infect study participants with a strain of RSV to see how the infections develops and investigate a possible treatment.

A new NIH study is just getting underway that will infect study participants with a strain of RSV (respiratory syncytial virus) to see how the infection develops and if anything can be done to create effective vaccines against the virus. The study will recruit 60 healthy adults between the ages of 18-50 who will likely only develop cold-like symptoms from having a drop of liquid containing RSV A2 placed in each nostril.

The participants will be given a low dose of RSV A2 or a high dose of the virus, with participants and researchers blinded as to who receives which dose. The participants will then be isolated in a hospital for up to two weeks, with parameters such as the symptoms the patient experiences, the way the immune system reacts to the infection, and air movement in and out of the participant’s lungs studied until the patient recovers from this self-limited lung disease.

Get the full story at www.lungdiseasenews.com